[LCID Study Number: 2018-043QURM]
BYLieve: A phase II, multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2- negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment
This is a phase II, multicenter, open-label, two-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in patients with HR+, HER2-negative aBC harboring PIK3CA mutation(s) in the tumor whose disease has progressed on or after CDK 4/6 inhibitor containing treatments.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-2734